Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.
Chemotherapy
Ifosfamide
Metastasis
Osteosarcoma
Survival
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
14
07
2019
accepted:
20
11
2019
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
The effectiveness of second-line palliative chemotherapy in patients with recurrent/metastatic osteosarcoma is not well defined. Several small studies (6-19 patients) have reported on ifosfamide as second-line treatment. In this study we report our single-center experience with second-line ifosfamide monotherapy in patients treated for recurrent/metastatic osteosarcoma. A chart review was conducted of all patients with osteosarcoma treated with ifosfamide from 1978 until 2017. Until 1997 a 5 g/m Sixty-two patients were selected with recurrent/metastatic osteosarcoma treated with second-line ifosfamide monotherapy (dose of 5 g/m This study suggests that ifosfamide is an effective second-line treatment for patients with recurrent/metastatic osteosarcoma. Ifosfamide monotherapy is commonly used as second-line treatment in osteosarcoma, although large series to support this are lacking. This retrospective study reports overall and progression-free survival for regimens with 5 g/m
Sections du résumé
BACKGROUND
The effectiveness of second-line palliative chemotherapy in patients with recurrent/metastatic osteosarcoma is not well defined. Several small studies (6-19 patients) have reported on ifosfamide as second-line treatment. In this study we report our single-center experience with second-line ifosfamide monotherapy in patients treated for recurrent/metastatic osteosarcoma.
METHODS
A chart review was conducted of all patients with osteosarcoma treated with ifosfamide from 1978 until 2017. Until 1997 a 5 g/m
RESULTS
Sixty-two patients were selected with recurrent/metastatic osteosarcoma treated with second-line ifosfamide monotherapy (dose of 5 g/m
CONCLUSION
This study suggests that ifosfamide is an effective second-line treatment for patients with recurrent/metastatic osteosarcoma.
IMPLICATIONS FOR PRACTICE
Ifosfamide monotherapy is commonly used as second-line treatment in osteosarcoma, although large series to support this are lacking. This retrospective study reports overall and progression-free survival for regimens with 5 g/m
Identifiants
pubmed: 32297446
doi: 10.1634/theoncologist.2019-0528
pmc: PMC7160412
doi:
Substances chimiques
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e716-e721Informations de copyright
© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Références
BMC Cancer. 2016 Apr 20;16:280
pubmed: 27098543
Pediatr Blood Cancer. 2004 Apr;42(4):320-4
pubmed: 14966827
J Clin Oncol. 2002 Feb 1;20(3):776-90
pubmed: 11821461
Pediatr Blood Cancer. 2010 Feb;54(2):216-21
pubmed: 19890902
J Clin Oncol. 1999 Jan;17(1):150-7
pubmed: 10458228
Lancet Oncol. 2019 Jan;20(1):120-133
pubmed: 30477937
J Clin Oncol. 2016 Sep 1;34(25):3031-8
pubmed: 27400942
J Clin Oncol. 1989 Jan;7(1):126-31
pubmed: 2491883
Oncology. 2011;80(3-4):257-61
pubmed: 21734417
J Clin Oncol. 2002 Jan 15;20(2):426-33
pubmed: 11786570
J Clin Oncol. 2008 Feb 1;26(4):633-8
pubmed: 18235123
J Clin Oncol. 1997 Jun;15(6):2378-84
pubmed: 9196153
Eur J Cancer. 1997 Feb;33(2):232-7
pubmed: 9135494
Acta Orthop. 2011 Apr;82(2):211-6
pubmed: 21434784
J Natl Cancer Inst. 2007 Jan 17;99(2):112-28
pubmed: 17227995
J Clin Oncol. 2005 Jan 20;23(3):559-68
pubmed: 15659502
Cancer Treat Rep. 1985 Jan;69(1):115-7
pubmed: 3855382
Lancet Oncol. 2016 Oct;17(10):1396-1408
pubmed: 27569442